18.28  0.45 (2.52%)		03-09 16:00
Open: 17.6 High: 18.36 Volume: 249,587		Pre. Close: 17.83 Low: 17.45 Market Cap: 688(M)

Short term
Mid term
Targets	6-month :	23.35	1-year :	25.63
Resists	First :	19.99	Second :	21.95
Pivot price	18.96
Supports	First :	16.84	Second :	14.01
MAs	MA(5) :	17.86	MA(20) :	19.32
	MA(100) :	18.11	MA(250) :	16.59
MACD	MACD :	-0.8	Signal :	-0.7
%K %D	K(14,3) :	27.7	D(3) :	23
RSI	RSI(14): 38.9
52-week	High :	24.32	Low :	10.01

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ CBLL ] has closed above bottom band by 32.2%. Bollinger Bands are 4.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	18 - 18.1	18.1 - 18.2
Low:	17.14 - 17.25	17.25 - 17.35
Close:	17.67 - 17.85	17.85 - 18.01

CeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company develops Ceribell System, a novel, point-of-care EEG platform to address the unmet needs of patients in the acute care setting. It also offers EEG disposable headbands; and pocket-sized battery-operated recorders. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. The company was incorporated in 2014 and is based in Sunnyvale, California.

Mon, 09 Mar 2026
Foehr David, senior VP at Ceribell, sells $81k in CBLL stock - Investing.com Nigeria

Thu, 05 Mar 2026
Ceribell CEO Chao sells $680k in CBLL stock By Investing.com - Investing.com Nigeria

Wed, 04 Mar 2026
Ceribell Earnings Call Highlights Strong Growth, Rising Costs - TipRanks

Mon, 02 Mar 2026
Cautious Guidance Offsets Solid Q4 for CeriBell, Inc. (CBLL), Says Canaccord - Yahoo Finance

Fri, 27 Feb 2026
CeriBell, Inc. (CBLL) Stock Analysis: Exploring a 43% Potential Upside in the Innovative Medical Devices Sector - DirectorsTalk Interviews

Tue, 24 Feb 2026
Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Devices
Shares Out	38 (M)
Shares Float	24 (M)
Held by Insiders	12.8 (%)
Held by Institutions	85.2 (%)
Shares Short	1,660 (K)
Shares Short P.Month	1,600 (K)

EPS	-1.47
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	4.13
Profit Margin	-60 %
Operating Margin	-58.9 %
Return on Assets (ttm)	-17.4 %
Return on Equity (ttm)	-30.9 %
Qtrly Rev. Growth	33.7 %
Gross Profit (p.s.)	2.07
Sales Per Share	2.36
EBITDA (p.s.)	-1.52
Qtrly Earnings Growth	0 %
Operating Cash Flow	-41 (M)
Levered Free Cash Flow	-24 (M)

PE Ratio	-12.53
PEG Ratio	0
Price to Book value	4.41
Price to Sales	7.72
Price to Cash Flow	-16.87

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.